Home/Pipeline/NK Cell + Antibody Combination

NK Cell + Antibody Combination

Cancer

Pre-clinicalActive

Key Facts

Indication

Cancer

Phase

Pre-clinical

Status

Active

Company

CiMaas

About CiMaas

CiMaas is a private, preclinical-stage biotech developing adoptive cell therapies centered on Natural Killer (NK) cells for oncology. Its core technology involves a proprietary feeder cell system (F012) for large-scale expansion of potent, donor-derived NK cells, which can be used alone, combined with therapeutic antibodies, or engineered into CAR-NK products. With a strong scientific advisory board and recent non-dilutive grant funding, the company is translating its platform from preclinical validation into clinical development for a broad range of solid tumors.

View full company profile

Therapeutic Areas

Oncology

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active